

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt as to the course of action you should take, you should consult your stockbroker, solicitor, accountant, banker or other professional adviser immediately.

Bursa Malaysia Securities Berhad has not perused this Circular before its issuance.

Bursa Malaysia Securities Berhad takes no responsibility for the contents of this Circular, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Circular.

Shareholders should rely on their own evaluation to assess the merits and risks of the proposal as set out herein.



CCM DUOPHARMA BIOTECH BERHAD

(Company No. 524271-W)
(Incorporated in Malaysia)

CIRCULAR TO SHAREHOLDERS IN RELATION TO THE

**PROPOSED CHANGE OF THE COMPANY'S NAME
FROM "CCM DUOPHARMA BIOTECH BERHAD"
TO "DUOPHARMA BIOTECH BERHAD"**

AND

NOTICE OF MEETING OF MEMBERS

The notice of the Meeting of Members of the Company which will be held at Ballroom 1, Setia City Convention Centre, No. 1, Jalan Setia Dagang AG U13/AG, Setia Alam, Seksyen U13, 40170 Shah Alam, Selangor Darul Ehsan, Malaysia on Wednesday, 20 February 2019 at 10.00 a.m., together with the Proxy Form are enclosed herein.

In the event you wish to appoint a proxy, please complete, sign and return the Proxy Form in accordance with the instructions printed thereon. The Proxy Form must be lodged with the Registrar, Tricor Investor & Issuing Houses Services Sdn Bhd, Unit 32-01, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia, not less than twenty-four (24) hours before the time appointed for taking of the poll as per Section 334(3) of the Companies Act 2016. The lodging of the Proxy Form will not preclude you from attending and voting in person at the Meeting of Members should you subsequently decide to do so.

Date and time of the Meeting of Members:

Wednesday, 20 February 2019 at 10.00 a.m.

Venue of the Meeting of Members:

Ballroom 1, Setia City Convention Centre, No. 1,
Jalan Setia Dagang AG U13/AG, Setia Alam,
Seksyen U13, 40170 Shah Alam, Selangor Darul
Ehsan, Malaysia.

This Circular is dated 14 January 2019.

DEFINITIONS

Except where the context otherwise requires, the following definitions shall apply throughout this Circular:

“Act”	:	Companies Act 2016
“Board”	:	The Board of Directors of CCM Duopharma
“Bursa Securities”	:	Bursa Malaysia Securities Berhad (635998-W)
“CCMB”	:	Chemical Company of Malaysia Berhad (5136-T)
“CCM Duopharma” or the “Company”	:	CCM Duopharma Biotech Berhad (524271-W)
“CCM Duopharma Group” or “Group”	:	CCM Duopharma and its subsidiaries
“Circular”	:	This Circular to shareholders dated 14 January 2019 in relation to the Proposed Change of the Company’s Name
“Constitution”	:	The constitution of the Company
“Directors”	:	Shall have the meaning given in Section 2 of the Act and Section 2(1) of the Capital Markets and Services Act 2007
“Korean Won” and “KRW”	:	The lawful currency of Korea
“LPD”	:	31 December 2018, being the last practicable date prior to the date of this Circular
“MOM”	:	Meeting of Members
“Proposed Change of the Company’s Name”	:	Proposed change of name of the Company from “CCM Duopharma Biotech Berhad” to “Duopharma Biotech Berhad”
“RM and Sen”	:	Ringgit Malaysia and Sen respectively, being the lawful currency of Malaysia
“Share(s)”	:	Ordinary Share(s)
“SSM”	:	Companies Commission of Malaysia

Words denoting the singular shall, where applicable, include the plural and vice versa and words denoting the masculine gender shall, where applicable, include the feminine and neuter gender and vice versa. Reference to persons shall include corporations.

Any reference in this Circular to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any reference to a time of day in this Circular shall be a reference to Malaysian time, unless otherwise stated.

The rest of this page has been intentionally left blank

TABLE OF CONTENTS

LETTER TO THE SHAREHOLDERS OF CCM DUOPHARMA IN RELATION TO THE PROPOSED CHANGE OF THE COMPANY'S NAME CONTAINING:-

1.	INTRODUCTION	1
2.	DETAILS OF THE PROPOSED CHANGE OF THE COMPANY'S NAME	2
3.	RATIONALE OF THE PROPOSED CHANGE OF THE COMPANY'S NAME	2
4.	EFFECTS OF THE PROPOSED CHANGE OF THE COMPANY'S NAME	2
5.	INTEREST OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED WITH THEM	2
6.	APPROVALS REQUIRED	3
7.	DIRECTORS' RECOMMENDATION	3
8.	MOM	3
9.	FURTHER INFORMATION	4
	APPENDIX I: FURTHER INFORMATION	5
	NOTICE OF MOM	ENCLOSED
	PROXY FORM	ENCLOSED

THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK

**LETTER TO THE SHAREHOLDERS OF CCM DUOPHARMA IN RELATION TO THE
PROPOSED CHANGE OF THE COMPANY'S NAME**



CCM DUOPHARMA BIOTECH BERHAD
(524271-W)
(Incorporated in Malaysia)

Registered Office:
Suite 18.06, Level 18, Kenanga International,
No. 26, Jalan Sultan Ismail,
50250 Kuala Lumpur,
Malaysia

14 January 2019

BOARD OF DIRECTORS

Tan Sri Datin Paduka Siti Sa'diah binti Sh. Bakir (*Non-Independent Non-Executive Chairman*)
Leonard Ariff bin Abdul Shatar (*Group Managing Director*)
Dato' Mohamad Kamarudin bin Hassan (*Senior Independent Non-Executive Director*)
Razalee bin Amin (*Independent Non-Executive Director*)
Puan Sri Datuk Seri Rohani Parkash binti Abdullah (*Independent Non-Executive Director*)
Zaiton binti Jamaluddin (*Independent Non-Executive Director*)
Dato' Eisah binti A. Rahman (*Independent Non-Executive Director*)
Datuk Nik Moustpha bin Hj Nik Hassan (*Independent Non-Executive Director*)
Datuk Mohd Radzif bin Mohd Yunus (*Non-Independent Non-Executive Director*)

To: The Shareholders of CCM Duopharma Biotech Berhad

Dear Sir/Madam,

PROPOSED CHANGE OF THE COMPANY'S NAME

1. INTRODUCTION

The Board had on 10 December 2018 made an announcement to Bursa Securities that the Company intended to seek the approval of its shareholders for the proposed change of the Company's name from "CCM Duopharma Biotech Berhad" to "Duopharma Biotech Berhad" ("Proposed Change of the Company's Name").

The purpose of this Circular is to provide you with information on the Proposed Change of the Company's Name and to seek your approval of the Special Resolution pertaining to the Proposed Change of the Company's Name to be tabled at the forthcoming MOM. The Notice of the forthcoming MOM and the Proxy Form are enclosed together with this Circular.

YOU ARE ADVISED TO READ AND CONSIDER CAREFULLY THE CONTENTS OF THIS CIRCULAR BEFORE VOTING ON THE SPECIAL RESOLUTION PERTAINING TO THE PROPOSED CHANGE OF THE COMPANY'S NAME AT THE FORTHCOMING MOM OF THE COMPANY.

2. DETAILS OF THE PROPOSED CHANGE OF THE COMPANY'S NAME

The proposed change of name of the Company from "CCM Duopharma Biotech Berhad" to "Duopharma Biotech Berhad" is pursuant to the Group's demerger from CCMB that was completed on 28 December 2017.

In conjunction with the Proposed Change of the Company's Name, the Constitution will be amended accordingly to reflect the Proposed Change of the Company's Name whereby all references in the Constitution to the name of "CCM Duopharma Biotech Berhad", wherever the same may appear, shall be substituted with the name "Duopharma Biotech Berhad".

3. RATIONALE FOR THE PROPOSED CHANGE OF THE COMPANY'S NAME

The Proposed Change of the Company's Name is part of the Group's rebranding strategy to position itself to have its own distinct corporate identity. It would also enable stakeholders to better differentiate between the Company and its former holding company i.e. CCMB.

4. EFFECTS OF THE PROPOSED CHANGE OF THE COMPANY'S NAME

The Proposed Change of the Company's Name will not have any effect on the share capital, substantial shareholders' shareholdings, net assets per share, gearing or earnings per share of the CCM Duopharma Group.

5. INTEREST OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED WITH THEM

None of the Directors and/or major shareholders and/or persons connected with them have any interest, direct or indirect, in the Proposed Change of the Company's Name.

6. APPROVALS REQUIRED

The use of the proposed name “Duopharma Biotech Berhad” has been approved and reserved by the SSM on 12 November 2018 and the reservation for the use of the proposed name was valid for a period of 30 days from 12 November 2018 (“Validity Period”). Subsequently, the Validity Period was extended by the SSM to 12 March 2019.

The Proposed Change of the Company’s Name is subject to the approval of the shareholders of the Company being obtained by way of a special resolution at the forthcoming MOM or at any adjournment thereof.

The Proposed Change of the Company’s Name, if approved by the shareholders, will take effect from the date of issuance of the Notice of Registration of New Name by the SSM to the Company.

7. DIRECTORS’ RECOMMENDATION

The Board, having considered all aspects of the Proposed Change of the Company’s Name, is of the opinion that the Proposed Change of the Company’s Name is in the best interest of the Company and accordingly, the Board recommends that you vote in favour of the special resolution pertaining to the Proposed Change of the Company’s Name to be tabled at the forthcoming MOM.

8. MOM

The MOM, the notice of which is enclosed in this Circular, is scheduled to be held at Ballroom 1, Setia City Convention Centre, No. 1, Jalan Setia Dagang AG U13/AG, Setia Alam, Seksyen U13, 40170 Shah Alam, Selangor Darul Ehsan, Malaysia on Wednesday, 20 February 2019 at 10.00 a.m. or any adjournment thereof, for the purpose of considering and if thought fit, passing with or without modification, the special resolution to give effect to the Proposed Change of the Company’s Name.

If you are unable to attend and vote at the MOM, you are requested to complete, sign and return the enclosed Proxy Form in accordance with the instructions contained therein, to be deposited at the Company’s Share Registrar, Tricor Investor & Issuing House Services Sdn Bhd at Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia, not less than twenty-four (24) hours before the time appointed for taking of the poll as per Section 334(3) of the Act. The lodging of the Proxy Form shall not preclude you from attending and voting in person at the MOM should you subsequently wish to do so.

9. FURTHER INFORMATION

Shareholders are advised to refer to the appendices set out in this Circular for further information.

Yours faithfully,
For and on behalf of the Board of Directors of
CCM DUOPHARMA BIOTECH BERHAD

TAN SRI DATIN PADUKA SITI SA'DIAH BINTI SH BAKIR
Chairman

FURTHER INFORMATION

1. RESPONSIBILITY STATEMENT

This Circular has been seen and approved by the Directors, who collectively and individually accept full responsibility for the accuracy of the information given and confirm that after having taken due care and making all reasonable inquiries, to the best of their knowledge and belief, there are no other material facts, the omission of which would make any statement herein misleading.

2. MATERIAL CONTRACTS

Save for the following, there were no material contracts entered into by the CCM Duopharma Group during the two (2) years preceding the date of this Circular, other than contracts entered into in the ordinary course of business:-

- (i) By way of a Share Subscription Agreement (“SSA”) dated 25 October 2018 made between CCM Duopharma of the first part, SCM Lifescience Co., Ltd. (“SCM Lifescience”) of the second part, Sun U. Song of the third part and Byung Geon Rhee of the fourth and last part (hereinafter Sun U. Song and Byung Geon Rhee are collectively referred to as the “Interested Persons”), SCM Lifescience had agreed to issue and sell and CCM Duopharma had agreed to subscribe for and purchase 164,016 common shares and 109,344 redeemable convertible preference shares representing approximately 5.8% equity stake in SCM Lifescience for a total purchase consideration of Korean Won (“KRW”) 5,500,003,200 upon the terms and conditions contained in the SSA;

In conjunction thereto, and by way of an Exclusive Marketing And Commercialization Agreement (“EMCA”) dated 25 October 2018 made between SCM Lifescience of the one part and CCM Duopharma of the other part, SCM Lifescience had agreed to grant the Company, in consideration of the Company paying to SCM Lifescience the sum of RM10.00 only upon execution of the EMCA and subject to the terms and conditions of the EMCA, (i) exclusive marketing and commercialization rights in Malaysia, Singapore, Brunei and Philippines (collectively “Principal ASEAN Territories”) for all the stem cell therapy products developed by SCM Lifescience; (ii) first right of refusal for exclusive marketing and commercialization rights for all other ASEAN countries, except Indonesia, for all the stem cell therapy products developed by SCM Lifescience; (iii) the technology transfer to the Company for any new future stem cell therapy business undertaken by the Company to the extent it is necessary for SCM Lifescience to fulfil the obligations under the EMCA; and (iv) the license regarding certain patents and

patent applications and related know-how to the extent it is necessary for SCM Lifescience to fulfil the obligations under the EMCA;

- (ii) By way of a Transitional Use Addendum dated 28 July 2018 made between CCM Duopharma, CCMB and SAP Malaysia Sdn. Bhd. ("SAP") to the SAP Software End-User License Agreement made between SAP and CCMB effective 1 September 2010 ("Initial Agreement") and all exhibits, appendices, schedules, order forms or other addenda attached to or referenced by the Initial Agreement (collectively the "Agreement"), SAP and CCMB agreed that CCM Duopharma and affiliates of CCM Duopharma shall have the right to use the software licensed by CCMB under the Agreement upon the terms and conditions therein contained;
- (iii) Facility Agreement for USD20.0 million Revolving Credit-i Commodity Murabahah entered into between CCM Duopharma and Oversea-Chinese Banking Corporation Limited, Labuan Branch, upon the terms and conditions as contained in the bank's Facility Letter dated 27 March 2018 and Supplemental Facility Letter dated 16 May 2018;
- (iv) By way of a conditional share sale agreement dated 13 April 2018 made between Chemical Company of Malaysia Berhad ("CCMB") of the one part and CCM Duopharma of the other part, CCM Duopharma had agreed to acquire from CCMB 806,450 common shares in PanGen Biotech Inc. representing approximately 8.39% equity interest in PanGen for a total purchase consideration of RM59.16 million (equivalent to KRW16.35 billion) to be satisfied entirely in cash and upon the terms and conditions therein contained;
- (v) By way of a Trade Marks License Agreement dated 11 April 2018 made between CCMB of the one part and CCM Duopharma of the other part, CCMB had agreed to grant the license and right for CCM Duopharma and its affiliates to use the trademarks associated with the "CCM Leaf logo" and "CCM" for a consideration of RM250,000 per annum and upon the terms and conditions therein contained, and by way of a sale and purchase agreement of trademarks dated 11 April 2018 made between CCMB and CCM Duopharma, CCMB had agreed to sell to CCM Duopharma certain trademarks which are pertinent to the operations of CCM Duopharma for a total purchase consideration of RM73.00 and upon the terms and conditions therein contained;
- (vi) By way of an Information Technology ("IT") Services Agreement dated 11 April 2018 made between CCMB of the one part and CCM Duopharma of the other part, CCMB had agreed to provide to CCM Duopharma IT management services, and systems, applications and products ("SAP") services upon the terms and conditions therein contained. The fees for the IT Services provided by CCMB to CCM Duopharma are as follows:

	IT Management Services	Charges per SAP user
Period	RM	RM per month
1 January 2018 – 31 December 2018	3,194,244	773
1 January 2019 – 31 December 2019	3,353,952	812
1 January 2020 – 31 December 2020	3,521,652	853
1 January 2018 – 31 December 2021	3,697,740	896

- (vii) By way of a Share Sale Agreement dated 27 February 2018 made between CCM Pharmaceuticals Sdn Bhd (“CCMP”) (a wholly-owned subsidiary of CCM Duopharma) of the one part and CCM Duopharma of the other part, CCMP had agreed to dispose its entire equity interest in CCM Biopharma Sdn Bhd (a wholly-owned subsidiary of CCMP) and Negeri Pharmacy Sdn Bhd (a wholly-owned subsidiary of CCMP) in favour of CCM Duopharma for a purchase consideration of RM2,500,000.00 and RM1.00 respectively and upon the terms and conditions therein contained;
- (viii) By way of a Share Sale Agreement dated 27 February 2018 made between Duopharma (M) Sdn Bhd (“DMSB”) (a wholly-owned subsidiary of CCM Duopharma) of the one part and CCM Duopharma of the other part, DMSB had agreed to dispose its entire equity interest in Upha Pharmaceutical Manufacturing (M) Sdn Bhd (“UPHA”) (a wholly-owned subsidiary of DMSB) in favour of CCM Duopharma for a purchase consideration of RM78,365,000.00 and upon the terms and conditions therein contained;
- (ix) By way of a Debt Conversion Agreement dated 27 February 2018 made between CCM Duopharma of the one part and UPHA (a wholly-owned subsidiary of DMSB) of the other part, the parties had agreed to increase the paid-up share capital of UPHA by way of conversion of a portion of inter-company loan owed by UPHA to CCM Duopharma amounting to RM90,000,000.00;

- (x) Proposed bonus issue announced by CCM Duopharma on 27 February 2018 of up to 371,945,333 new ordinary shares in CCM Duopharma (“CCMD Shares”) (“Bonus Shares”) to be credited as fully-paid up on the basis of 4 Bonus Shares for every 3 existing CCMD Shares held by the shareholders of CCM Duopharma at an entitlement date to be determined and announced later, and proposed establishment of a dividend reinvestment plan which will provide the shareholders of CCM Duopharma with an option to elect to reinvest their cash dividend declared by CCM Duopharma which includes any interim, final, special or any other cash dividend in CCMD Shares;
- (xi) Acceptance by DMSB, a wholly-owned subsidiary of CCM Duopharma, of a Letter of Offer from Pharmaniaga Logistics Sdn Bhd to supply pharmaceutical and/or non-pharmaceutical products as listed in the Letter of Offer to hospitals, clinics and others under the Government of Malaysia from 1 December 2017 until 30 November 2019 (or at such other date as directed by the Government) for a total estimated value of approximately RM156 million;
- (xii) Acceptance of a tender offer by the Government of Malaysia for Biocon Sdn Bhd to manufacture and supply, and for CCMP, a wholly owned subsidiary of CCM Duopharma, to deliver human insulin formulation under the Ministry of Health’s Off-Take Agreement Program, for a period of three (3) years commencing on 2 December 2016 until 1 December 2019 and the Off-Take Agreement in relation thereto dated 18 August 2017 between the Government of Malaysia (represented by the Malaysian Ministry of Health), Biocon Sdn Bhd and CCMP for a total consideration of RM300,040,500.00;
- (xiii) Credit Facilities Agreement dated 6 July 2017 for an additional amount RM10.0 million entered into between DMSB (a wholly owned subsidiary of CCM Duopharma) and OCBC Bank (Malaysia) Berhad, based on terms and conditions as contained in the bank’s offer letter dated 27 April 2017; and
- (xiv) Facility Agreement for Murabahah Tawarruq Term Financing-i Facility dated 16 June 2017 of RM250.0 million and Islamic Multi-Trade Facilities dated 19 May 2017 of RM30.0 million entered into between CCM Duopharma and AmBank Islamic Berhad.

3. MATERIAL LITIGATION, CLAIMS OR ARBITRATION

As at LPD, the CCM Duopharma Group is not engaged in any material litigation, claim or arbitration, either as plaintiff or defendant or otherwise, and the Board does not have any knowledge of any proceeding, pending or threatened against the CCM Duopharma Group, or of any fact likely to give rise to any such proceeding, which might materially or adversely affect the financial position or business of the CCM Duopharma Group.

4. DOCUMENTS AVAILABLE FOR INSPECTION

Copies of the following documents are available for inspection by shareholders of the Company at the Registered Office of the Company at Suite 18.06, Level 18, Kenanga International, No. 26, Jalan Sultan Ismail, 50250 Kuala Lumpur, Malaysia during normal business hours, from Monday to Friday (except public holidays) from the date of this Circular up to and including the date of the MOM:-

- (i) the Constitution;
- (ii) SSM's letter dated 12 November 2018 in respect of the reservation of the proposed name "Duopharma Biotech Berhad" and SSM's letter dated 10 December 2018 in respect of the extension of the name reservation period;
- (iii) the material contracts as set out in Section 2 of this Appendix; and
- (v) the audited consolidated financial statements of CCM Duopharma Group for the financial years ended 31 December 2016 and 31 December 2017.

THE REST OF THE PAGE HAS BEEN INTENTIONALLY LEFT BLANK



CCM DUOPHARMA BIOTECH BERHAD

(Company No.524271-W)

(Incorporated in Malaysia)

NOTICE OF MEETING OF MEMBERS

NOTICE IS HEREBY GIVEN THAT a Meeting of Members of CCM Duopharma Biotech Berhad (“CCM Duopharma” or the “Company”) will be held at the Ballroom 1, Setia City Convention Centre, No. 1, Jalan Setia Dagang AG U13/AG, Setia Alam, Seksyen U13, 40170 Shah Alam, Selangor Darul Ehsan, Malaysia on Wednesday, 20 February 2019, at 10.00 a.m, or at any adjournment thereof, for the purpose of considering and if thought fit, passing with or without modification the following resolution:

AS SPECIAL RESOLUTION

PROPOSED CHANGE OF NAME OF THE COMPANY FROM “CCM DUOPHARMA BIOTECH BERHAD” TO “ DUOPHARMA BIOTECH BERHAD” (“PROPOSED CHANGE OF THE COMPANY’S NAME”)

“**THAT** the name of the Company be hereby changed from “CCM Duopharma Biotech Berhad” to “Duopharma Biotech Berhad” with effect from the date of the Notice of Registration of New Name issued by the Companies Commission of Malaysia to the Company.

AND THAT the Constitution of the Company be hereby amended to substitute all references in the Constitution to “CCM Duopharma Biotech Berhad”, wherever the same may appear, with “Duopharma Biotech Berhad”, subject to and upon issuance of the Notice of Registration of New Name by the Companies Commission of Malaysia to the Company.

AND THAT the Directors and/or the Secretary of the Company be and are hereby authorised to take all such necessary steps and do all acts and things to give effect to the Proposed Change of the Company’s Name with full power to assent to any conditions, modifications, variations and/or amendments as may be required by the relevant authorities.”

BY ORDER OF THE BOARD

IBRAHIM HUSSIN SALLEH (LS0009121)

Company Secretary

Kuala Lumpur

14 January 2019

Notes:-

1. *The Special Resolution in the Notice of MOM is to be conducted by poll voting as per Paragraph 8.29A(1) of the Main Market Listing Requirements issued by Bursa Malaysia Securities Berhad.*
2. *A member entitled to attend and vote at the meeting is entitled to appoint not more than 2 proxies to attend and vote instead of him. A proxy may but need not be a member of the Company.*
3. *Where a member of the Company appoints 2 proxies, the appointment shall be invalid unless the member specifies the proportion of his shareholdings to be represented by each proxy.*
4. *Where a member of the Company is an exempt authorised nominee which holds ordinary shares in the Company for multiple beneficial owners in one securities account ("omnibus account"), there is no limit to the number of proxies which the exempt authorised nominee may appoint in respect of each omnibus account it holds.*
5. *An exempt authorised nominee refers to an authorised nominee defined under the Securities Industry (Central Depositories) Act 1991 ("SICDA") which is exempted from compliance with the provisions of subsection 25A(1) of SICDA.*
6. *The instrument appointing a proxy shall be in writing under the hand of the appointer or his attorney duly authorised in writing or, if the appointer is a corporation, either under seal or under the hand of an officer or attorney duly authorised.*
7. *The instrument appointing a proxy must be deposited at the Company's Registrar, Tricor Investor & Issuing House Services Sdn Bhd, Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, not less than twenty four (24) hours before the time appointed for the taking of the poll as per Section 334(3) of the Companies Act, 2016.*
8. *Only depositors whose names appear in the Record of Depositors as at 13 February 2019 shall be regarded as members and entitled to attend and vote at the meeting.*

Explanatory Notes To The Agenda:-

The explanatory notes on the proposed Special Resolution are set out in the Circular to Shareholders dated 14 January 2019.

PROXY FORM

CCM Duopharma Biotech Berhad
(Company No.: 524271-W) (Incorporated in Malaysia)

I/ We _____ NRIC. No./ Passport No./ Company No. _____
of _____

being *a shareholder/shareholders of CCM DUOPHARMA BIOTECH BERHAD ("the Company") hereby appoint:

Full Name (in Block)	NRIC/Passport No.	Proportion of Shareholdings	
Address		No. of shares	%

* and/or * delete if not applicable

Full Name (in Block)	NRIC/Passport No.	Proportion of Shareholdings	
Address		No. of shares	%

Or failing him/her, the Chairman of the Meeting *my/our proxy to vote for *me/our behalf at the Meeting of Members of the Company to be held at Ballroom 1, Setia City Convention Centre, No. 1, Jalan Setia Dagang AG U13/AG, Setia Alam, Seksyen U13, 40170 Shah Alam, Selangor Darul Ehsan, Malaysia on Wednesday, 20 February 2019 at 10.00 a.m., or at any adjournment thereof.

My/Our Proxy is to vote as indicated below:

RESOLUTION	FOR	AGAINST
SPECIAL RESOLUTION – PROPOSED CHANGE OF NAME OF THE COMPANY FROM "CCM DUOPHARMA BIOTECH BERHAD" TO "DUOPHARMA BIOTECH BERHAD"		

(Please indicate with an "X" how you wish to cast your vote)

Signed this _____ day of _____ 2019.

Signature/Seal

CDS Account No.	_____
No. of ordinary shares	_____

Notes:-

1. The Resolution in the Notice of MOM is to be conducted by poll voting as per Paragraph 8.29A(1) of the Main Market Listing Requirements issued by Bursa Malaysia Securities Berhad.
2. A member entitled to attend and vote at the meeting is entitled to appoint not more than 2 proxies to attend and vote instead of him. A proxy may but need not be a member of the Company.
3. Where a member of the Company appoints 2 proxies, the appointment shall be invalid unless the member specifies the proportion of his shareholdings to be represented by each proxy.
4. Where a member of the Company is an exempt authorised nominee which holds ordinary shares in the Company for multiple beneficial owners in one securities account ("omnibus account"), there is no limit to the number of proxies which the exempt authorised nominee may appoint in respect of each omnibus account it holds.
5. An exempt authorised nominee refers to an authorised nominee defined under the Securities Industry (Central Depositories) Act 1991 ("SICDA") which is exempted from compliance with the provisions of subsection 25A(1) of SICDA.
6. The instrument appointing a proxy shall be in writing under the hand of the appointer or his attorney duly authorised in writing or, if the appointer is a corporation, either under seal or under the hand of an officer or attorney duly authorised.
7. The instrument appointing a proxy must be deposited at the Company's Registrar, Tricor Investor & Issuing House Services Sdn Bhd, Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia, not less than twenty four (24) hours before the time appointed for the taking of the poll as per Section 334(3) of the Companies Act, 2016.
8. Only depositors whose names appear in the Record of Depositors as at 13 February 2019 shall be regarded as members and entitled to attend and vote at the meeting.



Fold this flap for sealing

Then fold here

AFFIX
STAMP

THE REGISTRAR
CCM DUOPHARMA BIOTECH BERHAD (Company No.: 524271-W)
Unit 32-01, Level 32, Tower A
Vertical Business Suite, Avenue 3
Bangsar South
No. 8, Jalan Kerinchi
59200 Kuala Lumpur
Wilayah Persekutuan Kuala Lumpur
Malaysia

1st fold here
